Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Dargaud

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 2, 2011
Evaluation of the overall haemostatic effect of recombinant factor VIIa by measuring thrombin generation and stability of fibrin clotsY Dargaud, C Prevost, A Lienhart, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|June 21, 2005
Management of pregnant women with increased risk of venous thrombosisY Dargaud, L Rugeri, J Ninet, et al.
Thrombosis Research|September 6, 2008
Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCCH Desmurs-Clavel, C Huchon, B Chatard, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 26, 2012
Global haemostasis and point of care testingY Dargaud, B Sorensen, M Shima, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 20, 2010
Thrombin generation in patients with factor XI deficiency and clinical bleeding riskL Rugeri, F Quélin, B Chatard, et al.
Annales De Dermatologie Et De Venereologie|May 15, 2012
[Delayed-type hypersensitivity to heparin: diagnosis and therapeutic management]A Nosbaum, P Pralong, A Rozieres, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 21, 2011
On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VIIB Sørensen, Y Dargaud, G Kenet, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 19, 2015
In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7N Enjolras, E Perot, S Le Quellec, et al.
Journal of Thrombosis and Haemostasis : JTH|April 1, 2008
Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: an in vitro studyY Dargaud, H Desmurs-Clavel, S Marin, et al.
Journal of Thrombosis and Haemostasis : JTH|October 31, 2009
Activated factor X cleaves factor VIII at arginine 562, limiting its cofactor efficiencyJ L Plantier, V Rolli, C Ducasse, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 2, 2011
Evaluation of the overall haemostatic effect of recombinant factor VIIa by measuring thrombin generation and stability of fibrin clotsY Dargaud, C Prevost, A Lienhart, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|June 21, 2005
Management of pregnant women with increased risk of venous thrombosisY Dargaud, L Rugeri, J Ninet, et al.
Thrombosis Research|September 6, 2008
Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCCH Desmurs-Clavel, C Huchon, B Chatard, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 26, 2012
Global haemostasis and point of care testingY Dargaud, B Sorensen, M Shima, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 20, 2010
Thrombin generation in patients with factor XI deficiency and clinical bleeding riskL Rugeri, F Quélin, B Chatard, et al.
Annales De Dermatologie Et De Venereologie|May 15, 2012
[Delayed-type hypersensitivity to heparin: diagnosis and therapeutic management]A Nosbaum, P Pralong, A Rozieres, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 21, 2011
On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VIIB Sørensen, Y Dargaud, G Kenet, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 19, 2015
In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7N Enjolras, E Perot, S Le Quellec, et al.
Journal of Thrombosis and Haemostasis : JTH|April 1, 2008
Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: an in vitro studyY Dargaud, H Desmurs-Clavel, S Marin, et al.
Journal of Thrombosis and Haemostasis : JTH|October 31, 2009
Activated factor X cleaves factor VIII at arginine 562, limiting its cofactor efficiencyJ L Plantier, V Rolli, C Ducasse, et al.
Pageof 4